Regeneron Pharmaceuticals, Inc.
Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties

Abstract:

The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.